Nanopublications

@prefix dc1: <http://purl.org/dc/terms/> .
@prefix this: <http://purl.org/np/RAVco7IKl4WeMnxQZLLvIbvg3Fsjc-TKrz-JoZCrZEUCA> .
@prefix sub: <http://purl.org/np/RAVco7IKl4WeMnxQZLLvIbvg3Fsjc-TKrz-JoZCrZEUCA#> .
@prefix schema: <https://schema.org/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix nt: <https://w3id.org/np/o/ntemplate/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix orcid: <https://orcid.org/> .
@prefix bl: <https://w3id.org/biolink/vocab/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:Head {
  this: np:hasAssertion sub:assertion ;
    np:hasProvenance sub:provenance ;
    np:hasPublicationInfo sub:pubinfo ;
    a np:Nanopublication .
}

sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_9538> bl:category bl:Disease .
  sub:association rdf:object <http://purl.obolibrary.org/obo/DOID_9538> ;
    rdf:predicate bl:treats ;
    rdf:subject <https://identifiers.org/drugbank:DB00480> ;
    a rdf:Statement ;
    rdfs:label "revlimid is a thalidomide analogue indicated for the treatment of patients with multiple myeloma mm in combination with dexamethasone 1 1 mm as maintenance following autologous hematopoietic stem cell transplantation auto hsct 1 1 transfusion dependent anemia due to low or intermediate 1 risk myelodysplastic syndromes mds associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities 1 2 mantle cell lymphoma mcl whose disease has relapsed or progressed after two prior therapies one of which included bortezomib 1 3 limitations of use revlimid is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia cll outside of controlled clinical trials 1 4 revlimid in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma mm revlimid is indicated as maintenance therapy in patients with mm following autologous hematopoietic stem cell transplantation auto hsct revlimid is indicated for the treatment of patients with transfusion dependent anemia due to low or intermediate 1 risk myelodysplastic syndromes mds associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities revlimid is indicated for the treatment of patients with mantle cell lymphoma mcl whose disease has relapsed or progressed after two prior therapies one of which included bortezomib revlimid is not indicated and is not recommended for the treatment of patients with cll outside of controlled clinical trials see warnings and precautions 5 5" ;
    bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    bl:provided_by <https://w3id.org/um/NeuroDKG> ;
    bl:relation schema:TreatmentIndication .
  <https://identifiers.org/drugbank:DB00480> bl:category bl:Drug .
}

sub:provenance {
sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 .
}

sub:pubinfo {
  sub:sig npx:hasAlgorithm "RSA" ;
    npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB" ;
    npx:hasSignature "AKGzVXAkh1pljS2u+vEiN8pgGcSLUZsSTzkVh9ZaVQyhswnkR9G05TcE9HlNVuaBub8A+EzG6zfEEQWdjRSweJNBrObYSCW2+y40KXhivkGBpIyJQt2i2ULAG6irGy9zVVp4gH0U70PKLqxbKvTBwb93BxlHt66U7NF8JaPJXaU=" ;
    npx:hasSignatureTarget this: .
  this: dc1:created "2021-07-03T12:50:52.635+02:00"^^xsd:dateTime ;
    dc1:creator orcid:0000-0002-1468-3557 ;
    nt:wasCreatedFromProvenanceTemplate <http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM> ;
    nt:wasCreatedFromPubinfoTemplate <http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM> ;
    nt:wasCreatedFromTemplate <http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs> .
}